- Home
- RMNI vs BMEA Comparison
RMNI vs BMEA Comparison
Compare RMNI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMNI
- BMEA
- Stock Information
- Founded
- RMNI 2005
- BMEA 2017
- Country
- RMNI United States
- BMEA United States
- Employees
- RMNI N/A
- BMEA N/A
- Industry
- RMNI Business Services
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- RMNI Consumer Discretionary
- BMEA Health Care
- Exchange
- RMNI Nasdaq
- BMEA Nasdaq
- Market Cap
- RMNI 179.1M
- BMEA 153.3M
- IPO Year
- RMNI N/A
- BMEA 2021
- Fundamental
- Price
- RMNI $2.50
- BMEA $4.19
- Analyst Decision
- RMNI Buy
- BMEA Buy
- Analyst Count
- RMNI 2
- BMEA 13
- Target Price
- RMNI $6.00
- BMEA $37.25
- AVG Volume (30 Days)
- RMNI 502.6K
- BMEA 1.1M
- Earning Date
- RMNI 10-30-2024
- BMEA 10-29-2024
- Dividend Yield
- RMNI N/A
- BMEA N/A
- EPS Growth
- RMNI N/A
- BMEA N/A
- EPS
- RMNI N/A
- BMEA N/A
- Revenue
- RMNI $426,650,000.00
- BMEA N/A
- Revenue This Year
- RMNI N/A
- BMEA N/A
- Revenue Next Year
- RMNI N/A
- BMEA N/A
- P/E Ratio
- RMNI N/A
- BMEA N/A
- Revenue Growth
- RMNI N/A
- BMEA N/A
- 52 Week Low
- RMNI $1.53
- BMEA $3.61
- 52 Week High
- RMNI $3.44
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- RMNI 63.97
- BMEA 24.17
- Support Level
- RMNI $1.95
- BMEA $3.81
- Resistance Level
- RMNI $3.00
- BMEA $6.06
- Average True Range (ATR)
- RMNI 0.17
- BMEA 0.56
- MACD
- RMNI 0.04
- BMEA -0.14
- Stochastic Oscillator
- RMNI 53.55
- BMEA 7.40
About RMNI Rimini Street Inc. (DE)
Rimini Street Inc is a provider of enterprise software support products and services and a third-party support provider for Oracle and SAP software products based in the United States. The company offers solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. Some of its products include Oracle E-business suite, Oracle Database, Peoplesoft, SAP business suite, and others. The company derives maximum revenue from United states.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.